Connect with ERS Genomics @SynBioBeta

We are delighted to attend and participate in SynBioBeta 2023.
ERS is the world’s leader in licensing of CRISPR/Cas9 technology for a wide variety of applications.
We know that the CRISPR licensing landscape can seem confusing, but we’re here to help provide specific information relevant to your specific situation.

SynbioBeta is the perfect time to start a conversation about your CRISPR license. We are excited to connect with companies who can benefit from this game-changing technology.


A meeting or a call with us is worthwhile for you if:

  • You are interested in possible use of CRISPR/Cas9 for internal research programs.

  • You utilise CRISPR/Cas9 for Industrial Bio-production for applications such
    as: Cultivated Food, Biofuels, Unique materials and plastics, Dyes/flavors/fragrances, microbes, enzymes, synthetic biology & sequencing tools.

  • You are interested in use of genetically modified cells in manufacturing of mAbs or
    viral vectors.

  • You provide services which utilise CRISPR/Cas9 or cells or animals modified by the
    technology. I ncluding: High-throughput screening, Target identification,
    Target validation, oligomer writing/synthesis tools, bio validation of AI
    platforms.

  

Let’s schedule a meeting in Oakland.


Paul Carter
Sr. Director Business Development & Licensing, North America

Licensing

Intellectual Property

Knowledge Centre

Contact US

The facts about CRISPR/Cas9 Licensing

When it comes to the CRISPR/Cas9 patent licensing landscape there is a lot of misinformation in circulation. Here, we provide straightforward answers to some of the most common misperceptions…

CRISPR/Cas9 For Rapid Vaccine Development

The application of CRISPR/Cas9 provides a novel platform in the development of recombinant viral vaccines through improvements in vaccine design and experimental vaccination approaches across…

CRISPR/Cas9 for Therapeutic Protein Production

Monoclonal antibodies (mAbs), as well as their derivative products including antibody-drug conjugates, Fc-fusion proteins, and antibody fragments, are well recognized for their vast range of therapeutic and diagnostic uses…